Mantle Cell Lymphoma

There are many exciting advances happening in the field of mantle cell lymphoma.

Since its classification in 1994, the prognosis for patients diagnosed with mantle cell lymphoma (MCL) was generally poor; however, survival rates have nearly doubled thanks to improvements in the treatment landscape over the past 10 years.

Moving from shock to action is hard, but it's critical to surviving cancer

Patients with mantle cell lymphoma (MCL) who were treated with Venclexta (venetoclax) showed a slight improvement in response rates compared with chemoimmunotherapy.

Sometimes the people who inspire us are closer than we realize.

Do you know the difference between happiness and joy?

A higher complete response rate was seen in patients given both agents compared with those given Imbruvica alone.

The treatment landscape of mantle cell lymphoma is continuing to change. See what expert Andre Goy, M.D., has to say about it.

Tavalisse (fostamatinib) was granted approval by the Food and Drug Administration (FDA) for patients with chronic immune thrombocytopenia (ITP) after they had an insufficiencent response to another therapy.

Kevin unleashes his inner guilt for the benefit of you, gentle readers.

You walk in and the entire staff yells your name, al la “Norm” of Cheers fame

Grzegorz S. Nowakowski, M.D., discusses the potential for genetic testing for patients with mantle cell lymphoma.

A non-runner explains why running and cancer are the same thing. Except they're not.

Andre Goy, M.D., discusses some exciting advances in mantle cell lymphoma (MCL).

In this episode of Cancer With Kevin, we explore the unexpected humor that comes with the general awfulness

Cancer quickly becomes your new, unwelcome, family business

Adding Ibrance to Imbruvica may be a promising treatment strategy for patients with mantle cell lymphoma, according to a recent study.

After two transplants and two relapses, it's time to go down a novel road.

If you've relapsed after you thought you'd been cured, you know what a shock it is. Relapsing twice, after two transplants, turns out to have a surprisingly different effect on Kevin.

Kevin compares building and fighting robots with enduring and fighting cancer-- a surprising synergy!

Life after cancer calls for yet another new normal.

Most cancer survivors are familiar with Psalm 23 and the feeling of walking through the valley of the shadow. We also need to remember that there's another side to the valley, where the light shines brightly.

The recent World Health Organization announcement classifying processed meat as a Group 1 carcinogen isn't really news. It's just common sense.

Kevin realizes that the trauma caused by losing space shuttles turns out to feel a lot like finding out you have cancer — only lonelier.

Two transplants, three mini triathons. Running the race for myself and others shows how lessons learned in the hospital translate to victory on the outside.

Kevin gives advice for giving advice.

Returning to the mechanics of transplant, Kevin gives some details of the six-month milestone, but is unable to refrain from a bit of hopeful philosophy.

Kevin gets philosophical, sharing deeply wrought insights in a manner that, just possibly, might actually make sense

Kevin continues to explain how to stay alive in a world that's pretty much trying to do the other thing to you.

Kevin explains, in a rather tedious manner, his procedure for washing his hands and other immune-deficient oddities.